Biofrontera (BFRI) to Release Earnings on Wednesday

Biofrontera (NASDAQ:BFRI) is expected to release its Q2 2025 earnings data after the market closes on Wednesday, August 13th. Analysts expect Biofrontera to post earnings of ($0.45) per share and revenue of $8.30 million for the quarter.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.33). The business had revenue of $8.59 million during the quarter, compared to analyst estimates of $10.55 million. Biofrontera had a negative net margin of 30.33% and a negative return on equity of 305.13%. On average, analysts expect Biofrontera to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biofrontera Price Performance

Shares of NASDAQ:BFRI opened at $0.92 on Tuesday. The firm has a 50 day simple moving average of $0.80 and a 200 day simple moving average of $0.84. The company has a market cap of $9.30 million, a price-to-earnings ratio of -0.41 and a beta of 0.50. Biofrontera has a one year low of $0.54 and a one year high of $2.22. The company has a debt-to-equity ratio of 8.99, a current ratio of 1.40 and a quick ratio of 0.80.

Analysts Set New Price Targets

Separately, Benchmark lowered their target price on Biofrontera from $7.00 to $2.75 and set a “buy” rating for the company in a research report on Monday, May 19th.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.